AZD1480是一种新型的ATP竞争性JAK2抑制剂，IC₅₀值为0.26 nM。AZD1480能够选择性作用于Tyk2和JAK3，但对JAK1的作用较弱。AZD1480对各种骨髓瘤细胞有效，可作为治疗多发性骨髓瘤的潜在新型治疗剂。

参考文献

1.Derenzini E, et al. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J. 2011 Dec;1(12):e46.

2.Scuto A, et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia. 2011 Mar;25(3):538-50.

3.McFarland BC, et al. Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther. 2011 Dec;10(12):2384-93.

3.Xin Y, et al. AZD1480 can inhibit the biological behavior of ovarian cancer SKOV3 cells in vitro. Asian Pacific Journal of Cancer Prevention, 2013, 14(8): 4823-4827.

4.Xin H, et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 2011 Nov 1;71(21):6601-10.

冰袋运输。粉末直接保存于-20℃，有效期2年。建议分装后-20℃避光保存，避免反复冻融。